Proprio’s Fourth FDA Clearance Highlights Growing Shift to 3D Measurement in Spine Care

SEATTLE, Jan. 15, 2026 /PRNewswire/ -- Proprio, the surgical technology company pioneering real-time, AI-powered intraoperative guidance and data-driven surgical workflows, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for the "Picasso" feature. This marks the company's fourth FDA-cleared capability within its Paradigm platform.

The Paradigm AI platform provides continuous, three-dimensional measurements that allow surgeons to assess spinal alignment intraoperatively. Growing clinical research has underscored the limitations of traditional two-dimensional assessment and the value of richer 3D characterization in understanding spinal anatomy and alignment.

The Picasso clearance expands Paradigm’s surgeon-controlled registration workflow, enabling trace-based optical registration within the Paradigm system to support intraoperative spinal alignment measurement across a broader range of spine procedures. This latest company milestone builds on Proprio’s radiation-free guidance foundation and reflects accelerated progress toward more precise, measurement-driven surgical workflows.

Sign up for Blog Updates